WIRB-Copernicus Group to Host Webinar on Emerging Ethical and Regulatory Considerations for Research in Oncology

This session will help attendees evaluate whether their institutional review boards (IRBs) are fully prepared to review the latest oncology research

PRINCETON, N.J., June 29, 2015 – WIRB-Copernicus Group® (WCG™), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that it will host a live, one-hour webinar entitled “New Therapeutic Innovations in Oncology Research: Is Your IRB Ready?” on Tuesday, June 30 at 3:00 pm EDT/12:00 pm PDT.

The leader in oncology review, WCG currently oversees more than 1,000 oncology research protocols at more than 4,000 sites across the U.S. In recognition of the growing complexity in oncology research, WCG established WCG Oncology™, a division focused wholly on the ethical and regulatory oversight of oncology research. In addition to three specialized IRBs, WCG Oncology is supported by a cadre of oncological consultants, who are each expert in a specific cancer-related discipline or area of research.

“Clinical trial designs have become more complex to accommodate recent advances in personalized medicine, immunotherapy and human gene transfer,” said Lindsay McNair, MD, MPH, MS Bioethics, chief medical officer and president of consulting services at WCG, and a former member of the Boston University Medical Center IRB. “With this increased complexity comes new ethical and regulatory considerations for IRBs reviewing oncology research.”

Dr. McNair will host this webinar together with guest speaker George D. Demetri, MD, senior vice president for experimental therapeutics at the Dana-Farber Cancer Institute, professor of medicine at Harvard Medical School, and an IRB member at the Dana-Farber/Harvard Cancer Center. Dr. Demetri is also a member of WCG’s Oncology Advisory Board, which provides guidance and strategic counsel to WCG on the rapidly-evolving oncology research landscape.

“As a clinician, researcher and IRB member, I fully appreciate the challenge of evaluating complex, cutting-edge oncology research,” said Dr. Demetri. “I am delighted to support WCG in finding new ways to enhance subject protection and to increase the quality of research oversight in oncology.”

During the webinar, Drs. McNair and Demetri will describe the latest oncology agents, discuss the ethical and regulatory issues inherent in recent therapeutic and clinical trial design advances, and help attendees assess whether their IRB is appropriately prepared to review this innovative research.

To register for this complimentary webinar, please visit https://goto.webcasts.com/starthere.jsp?ei=1067866.

About WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is the world’s largest provider of regulatory and ethical solutions for clinical research. The company provides Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) reviews, and Human Research Protection (HRP), Good Clinical Practice (GCP) and Biosafety consulting services. Its technology offerings include IRB workflow management solutions (IRBNet), clinical trial management software for sponsors and contract research organizations (ePharmaSolutions), and Part-11 compliant online learning solutions for research professionals (WCG Academy).

The pioneer of independent ethical oversight, WCG continues to drive progress in the clinical research space. WCG empowers clients to accelerate life-saving advancements, while ensuring that the risks of progress never outweigh the value of human life.

For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

Download the Press Release
[wpdm_package id=’2672′]